How Indian pharma is eyeing the weight-loss drug alternative

As Ozempic’s patent expiry nears, Indian pharma corporations are gearing as much as seize the worldwide GLP-1 weight-loss drug alternative. We map the provision chain, key gamers and potential winners — from APIs to injectors.